Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110043/S015

Omnilink Elite Vascular Balloon-Expandable Stent System

Abbott Vascular-Cardiac Therapies · Decision date Jan 12, 2026

FDA DECISIONP110043/S015

What did the FDA approve?

FDA records P110043/S015 as a supplement to PMA P110043, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jan 12, 2026.

FDA approval order statement

Approval for updates to the device Instructions for Use (IFU) and patient guide including updates to the contraindications, warnings, precautions, procedural updates, and MRI Safety information
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Jan 12, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P110043/S015
Regulatory pathway
PMA supplement
Product code
NIO
Decision code
APPR
Decision date
Jan 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, ILIAC.

Product code
NIO
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P110043/S015 received

    Application receipt date recorded by FDA.

  2. P110043/S015 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P110043. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code NIO

Product / regulatory recordCompanyPathwayDecision dateSource
Cook Ireland, Ltd.PMA supplementNov 6, 2026FDA
Medtronic Vascular, Inc.PMA supplementOct 16, 2026FDA
Cordis US CorporationPMA supplementOct 15, 2026FDA
Biotronik AGPMA supplementSep 11, 2026FDA
Boston Scientific CorpPMA supplementAug 21, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Vascular-Cardiac Therapies

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3200 Lakeside Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records